TABLE 2.
Use of drugs to treat pulmonary arterial hypertension (PAH) within 3 months and 1, 2 and 3 years (±6 months) after diagnosis
| 3 months (n=2375) | 1 year (n=2136) | 2 years (n=1727) | 3 years (n=1299) | |
| No therapy | 8 (0.3) | 73 (3.4) | 61 (3.5) | 48 (3.7) |
| Monotherapy | 1901 (80.0) | 1146 (53.7) | 841 (48.7) | 604 (46.5) |
| ERA | 401 (21.1) | 223 (19.5) | 145 (17.2) | 99 (16.4) |
| PDE5i | 1375 (72.3) | 851 (74.3) | 642 (76.3) | 467 (77.3) |
| sGC | 63 (3.3) | 40 (3.5) | 31 (3.7) | 23 (3.8) |
| PCA | 6 (0.3) | 3 (0.3) | 1 (0.1) | 1 (0.2) |
| PCA oral or inhaled# | 1 (16.7) | 2 (66.7) | 1 (100.0) | 0 (0.0) |
| PCA i.v. or s.c.¶ | 5 (83.3) | 1 (33.3) | 0 (0.0) | 1 (100.0) |
| CCB | 51 (2.7) | 29 (2.5) | 22 (2.6) | 14 (2.3) |
| Other PAH treatment | 5 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Combination therapy | 466 (19.6) | 917 (42.9) | 825 (47.8) | 647 (49.8) |
| ERA+PDE5i | 320 (68.7) | 619 (67.5) | 539 (65.3) | 400 (61.8) |
| Other than ERA+PDE5i | 146 (31.3) | 298 (32.5) | 286 (34.7) | 247 (38.2) |
| ERA+PDE5i+PCA | 33 (22.6) | 106 (35.6) | 110 (38.5) | 104 (42.1) |
| Triple combination therapy including i.v. or s.c. PCA+ | 21 (14.4) | 44 (14.8) | 47 (16.4) | 45 (18.2) |
Data are presented as n (%); percentages refer to subgroups only, if applicable. ERA: endothelin receptor antagonist; PDE5i: phosphodiesterase-5 inhibitor; sGC: soluble guanylate cyclase stimulator; PCA: prostacyclin analogue; CCB: calcium channel blocker. #: selexipag, iloprost inhaled, treprostinil inhaled, beraprost; ¶: epoprostenol, iloprost i.v., treprostinil i.v./s.c.; +: all triple combination therapies that include i.v. or s.c. PCA therapy.